• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Influence of the duration of topical 13-cis-retinoic acid treatment on inhibition of mouse skin tumor promotion.

作者信息

Gensler H L, Sim D A, Bowden G T

出版信息

Cancer Res. 1986 Jun;46(6):2767-70.

PMID:3084077
Abstract

The effect of the time and duration of retinoid treatment on the inhibition of Stage II tumor promotion by 12-O-tetradecanoylphorbol-13-acetate (TPA) was studied in CD-1 mice. All mice were initiated with 400 nmol of benzo(a)pyrene and received Stage I tumor promotion (3.2 nmol of TPA twice weekly for 2 wk). Animals were then randomized into groups which received 13-cis-retinoic acid during early, middle, or late Stage II promotion. 13-cis-Retinoic acid pretreatments starting on Day 1, Wk 8, or Wk 23 of Stage II promotion resulted in 47, 28, or 19% inhibition, respectively, of TPA-induced tumor formation. One-half of the mice receiving 13-cis-retinoic acid at Day 1 or Wk 8 were removed from the retinoid treatments at Wk 23, the time of cessation of TPA promotion. The inhibition of tumor formation remained constant during the 15-wk observation period after cessation of retinoid treatment, suggesting that retinoid inhibition of mouse skin tumor promotion is stable in the absence of further promotion and preceded the step of irreversible conversion of promoter dependence to promoter independence.

摘要

相似文献

1
Influence of the duration of topical 13-cis-retinoic acid treatment on inhibition of mouse skin tumor promotion.
Cancer Res. 1986 Jun;46(6):2767-70.
2
Inhibition of both stage I and stage II mouse skin tumour promotion by retinoic acid and the dependence of inhibition of tumor promotion on the duration of retinoic acid treatment.维甲酸对小鼠皮肤肿瘤促进I期和II期的抑制作用以及肿瘤促进抑制对维甲酸治疗持续时间的依赖性。
Cancer Res. 1987 Oct 1;47(19):5097-101.
3
Effects of dietary retinyl palmitate or 13-cis-retinoic acid on the promotion of tumors in mouse skin.
Cancer Res. 1987 Feb 15;47(4):967-70.
4
Inhibition of 7-bromomethylbenz[a]anthracene-promoted mouse skin tumor formation by retinoic acid and dexamethasone.维甲酸和地塞米松对7-溴甲基苯并[a]蒽促进的小鼠皮肤肿瘤形成的抑制作用。
Cancer Res. 1983 Jul;43(7):3045-9.
5
Inhibition of skin tumorigenesis by rosemary and its constituents carnosol and ursolic acid.迷迭香及其成分鼠尾草酸和熊果酸对皮肤肿瘤发生的抑制作用。
Cancer Res. 1994 Feb 1;54(3):701-8.
6
Inhibition of tumor promoter 12-O-tetradecanoylphorbol-13-acetate-induced synthesis of epidermal ornithine decarboxylase messenger RNA and diacylglycerol-promoted mouse skin tumor formation by retinoic acid.维甲酸对肿瘤启动子12 - O - 十四烷酰佛波醇 - 13 - 乙酸酯诱导的表皮鸟氨酸脱羧酶信使核糖核酸合成及二酰基甘油促进的小鼠皮肤肿瘤形成的抑制作用。
Cancer Res. 1988 Apr 15;48(8):2168-73.
7
The protein kinase C activator L-alpha-dioctanoylglycerol: a potent stage II mouse skin tumor promoter.蛋白激酶C激活剂L-α-二辛酰甘油:一种强效的II期小鼠皮肤肿瘤促进剂。
Cancer Res. 1988 Apr 1;48(7):1736-9.
8
Inhibitory effect of curcumin, chlorogenic acid, caffeic acid, and ferulic acid on tumor promotion in mouse skin by 12-O-tetradecanoylphorbol-13-acetate.姜黄素、绿原酸、咖啡酸和阿魏酸对12-O-十四烷酰佛波醇-13-乙酸酯诱导小鼠皮肤肿瘤促进作用的抑制效果。
Cancer Res. 1988 Nov 1;48(21):5941-6.
9
Inhibition of initiator-promoter-induced skin tumorigenesis in female SENCAR mice fed a vitamin A-deficient diet and reappearance of tumors in mice fed a diet adequate in retinoid or beta-carotene.在喂食维生素A缺乏饮食的雌性SENCAR小鼠中,起始-启动子诱导的皮肤肿瘤发生受到抑制,而在喂食类视黄醇或β-胡萝卜素充足饮食的小鼠中肿瘤重新出现。
Cancer Res. 1989 Oct 1;49(19):5400-6.
10
Inhibition of 12-O-tetradecanoylphorbol-13-acetate induction of ornithine decarboxylase activity, DNA synthesis, and tumor promotion in mouse skin by ascorbic acid and ascorbyl palmitate.抗坏血酸和抗坏血酸棕榈酸酯对12 - O - 十四烷酰佛波醇 - 13 - 乙酸酯诱导小鼠皮肤鸟氨酸脱羧酶活性、DNA合成及肿瘤促进作用的抑制
Cancer Res. 1987 Dec 15;47(24 Pt 1):6633-8.